companies

Enthera

Founded 2016
Employees 15+
Primary contact
Via Gioberti, 8
20123 Milano
Italy
+39 02 49533580
Links
https://www.entherapharmaceuticals.com/
Diseases & Conditions
Sections
Enthera is a biotech company building a pipeline of first-in-class biologics for several underserved autoimmune conditions, with a focus on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). It aims to develop disease-modifying treatments by preserving and re-establishing cell and organ function to revert the outcome of these conditions. Enthera's therapeutics are founded on the novel scientific discovery of a pathway, the IGFBP3/TMEM219 axis, found to be involved in stem cell apoptosis in the gut, as well as pancreatic and other tissues. IGFBP3 (Insulin Like Growth Factor Binding Protein 3) has been identified as a new enterostaminine that plays a key role in the pathogenesis of some autoimmune diseases, creating a new target and therapeutic approach.
Select partners: San Raffaele Hospital, University of Milan, Trianni, Yumab.
Founded 2016
Employees 15+
Primary contact
Via Gioberti, 8
20123 Milano
Italy
+39 02 49533580
Links
https://www.entherapharmaceuticals.com/
Diseases & Conditions
Sections

Funding 💰

Total €39M
Select investors Sofinnova Partners, AbbVie Ventures, Roche Venture Fund, Indaco Venture Partners, Banor SIM, BiovelocITA

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Novel therapeutic concept: The company's pioneering approach is to target IGFBP3/TMEM219, a novel stem cell apoptosis pathway involved in the development and progression of several autoimmune conditions. By targeting the IGFBP3/TMEM219 axis and its dysregulation, it aims to provide safe and effective therapeutics for autoimmune diseases with high unmet medical need.
  • Discovery engine: Enthera's proprietary discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway. These selective inhibitors abrogate the binding capability of IGFBP3 to the TMEM219 receptor using multiple approaches at different stages of the pathway.
  • Underserved medical conditions: The company is developing a portfolio of first-in-class selective inhibitors to treat intractable autoimmune diseases that cannot be prevented and for which there is no cure and only treatments with high rates of failure. No existing approach is able to restore the endogenous stem cell compartment and stem cell capabilities impaired by these conditions.
  • Solid pipeline: Enthera's current focus is the in-house development of two clinical candidates. Ent001, the lead program, is the only drug in development with the potential to preserve and restore the endogenous pancreatic beta cells compartment in Type 1 Diebetes as well as the original intestine structure in IBD, in order to re-stablish organ function. 🔗

Video ▶️

Last update: March 17, 2023